{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000030","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.152148+00:00","generated_at":"2026-06-24T02:47:16.361616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M","bullets":["Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.","Total revenue $1.3M from BMS collaboration, down from $60.1M in Q2 2021 which included Roche revenue.","Cash and restricted cash $510.1M at June 30, 2022; no debt.","FDA Fast Track granted for PRX012 (anti-Aβ antibody for Alzheimer's); topline Phase 1 data for PRX005 expected by year-end 2022.","Full-year 2022 net cash used in operations and investing expected $120-$132M; year-end cash ~$454M."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000030","json":"https://secwatch.observer/filing/0001559053-22-000030.json","markdown":"https://secwatch.observer/filing/0001559053-22-000030.md","text":"https://secwatch.observer/filing/0001559053-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/0001559053-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/prta-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:47:16.361616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}